BioHarvest Sciences Inc Dossier
|
SectorHealth Care IndustryPharmaceuticals Beta (adjusted)1.27 Intrinsic Value No headline value published yetWe haven't published a headline intrinsic value for this company yet. Our data-reliability standards weren't met. Method estimates are shown for reference. Market Price $1.49Price as of 1 Oct 2026 Data confidence Sign in to view data confidence Market Cap $33.8M Enterprise Value $10.9M Shares Outstanding 22.7M diluted Next Earnings Date12 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary BioHarvest Sciences Inc. (NASDAQ: BHST) is a pioneer in Botanical Synthesis, utilizing its patented plant cell biology platform to grow complex plant-based compounds without cultivating the actual plant. The company operates a high-margin dual business model: a Direct-to-Consumer (D2C) nutraceuticals division (anchored by its flagship VINIA brand) and a high-growth Contract Development and Manufacturing Organization (CDMO) division targeting pharmaceutical, fragrance, and sweetener industries. With a robust cash position of $20.2 million as of March 31, 2026, and a clear path to scaling production capacity, BHST is well-positioned to capture significant market share in sustainable biotechnology. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$10.00 Mean target$12.75 High · most bullish analyst$15.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $10.0015% Delays in the construction or regulatory approval of the new manufacturing facility push operational timelines past 2027. High customer acquisition costs or a slower-than-expected recovery in D2C sales post-marketing reset could prolong cash burn and necessitate dilutive capital raises. Base CaseCentral scenario $12.0060% BHST achieves its 2026 consolidated revenue guidance of $42M to $48M, driven by steady VINIA subscriber growth and execution of Stage 2 CDMO contracts. The company continues to narrow its operating losses as it prepares its new manufacturing facility for H2 2027 operations. Bull CaseUpside scenario $15.0025% Rapid commercialization of CDMO projects (including saffron and rare fragrances) combined with successful scaling of the new manufacturing facility by 2027. D2C margins expand beyond 60% as the LTV/CAC ratio optimizes, driving the company to consolidated profitability ahead of schedule. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |